{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Atypical haemolytic uraemic syndrome",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_eculizumab",
          "name": "Eculizumab"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_ravulizumab",
          "name": "Ravulizumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_avacopan",
          "name": "Avacopan"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_complement_c5_inhibitors",
          "name": "Complement C5 Inhibitors"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_cangrelor",
          "name": "Cangrelor"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_nivolumab",
          "name": "Nivolumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_eculizumab_biosimilar",
          "name": "Eculizumab Biosimilar"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_tafamidis",
          "name": "Tafamidis"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_ertugliflozin",
          "name": "Ertugliflozin"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_daratumumab",
          "name": "Daratumumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_obinutuzumab",
          "name": "Obinutuzumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_caplacizumab",
          "name": "Caplacizumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 3
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_eculizumab",
          "type": "Drug",
          "label": "Eculizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ravulizumab",
          "type": "Drug",
          "label": "Ravulizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_avacopan",
          "type": "Drug",
          "label": "Avacopan",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_complement_c5_inhibitors",
          "type": "Drug",
          "label": "Complement C5 Inhibitors",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cangrelor",
          "type": "Drug",
          "label": "Cangrelor",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_nivolumab",
          "type": "Drug",
          "label": "Nivolumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_eculizumab_biosimilar",
          "type": "Drug",
          "label": "Eculizumab Biosimilar",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tafamidis",
          "type": "Drug",
          "label": "Tafamidis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ertugliflozin",
          "type": "Drug",
          "label": "Ertugliflozin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_daratumumab",
          "type": "Drug",
          "label": "Daratumumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_obinutuzumab",
          "type": "Drug",
          "label": "Obinutuzumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_caplacizumab",
          "type": "Drug",
          "label": "Caplacizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_a_hus",
          "type": "Disease",
          "label": "Atypical Haemolytic Uraemic Syndrome",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_c5",
          "type": "Target",
          "label": "C5 Complement Protein",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_complement_system",
          "type": "Pathway",
          "label": "Complement System Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_eculizumab",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "已知机制，多项研究支持其用于aHUS"
        },
        {
          "source": "drug_ravulizumab",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "与eculizumab具有相似机制，预期疗效"
        },
        {
          "source": "drug_avacopan",
          "target": "pathway_complement_system",
          "relation": "modulates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "已知与补体系统交互的机制"
        },
        {
          "source": "drug_complement_c5_inhibitors",
          "target": "pathway_complement_system",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "补体抑制剂归入此类机制"
        },
        {
          "source": "drug_cangrelor",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "潜在关联性，有研究指向抗血小板作用"
        },
        {
          "source": "drug_nivolumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "需要进一步研究，但部分临床观察相关"
        },
        {
          "source": "drug_eculizumab_biosimilar",
          "target": "target_c5",
          "relation": "inhibits",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "作为原药物的生物仿制药，假设功能相似"
        },
        {
          "source": "drug_tafamidis",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "尚需验证但具有潜在机制的药物"
        },
        {
          "source": "drug_ertugliflozin",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "近期有初步研究显示效果"
        },
        {
          "source": "drug_daratumumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "针对特定病理机制，需深入探讨"
        },
        {
          "source": "drug_obinutuzumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.4,
          "agent": "Proponent",
          "rationale": "有针对性，初步数据待确认"
        },
        {
          "source": "drug_caplacizumab",
          "target": "disease_a_hus",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "已在临床试验中显示疗效"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物（如Eculizumab和Ravulizumab）通过补体C5靶点作用于aHUS",
        "confidence": "high"
      },
      {
        "id": "C2",
        "text": "Avacopan和Complement C5 Inhibitors可能通过补体通路调节疾病进程",
        "confidence": "medium"
      },
      {
        "id": "C3",
        "text": "其它药物如Cangrelor、Nivolumab展现潜在关联，但机制不明确",
        "confidence": "medium"
      }
    ],
    "assumptions": [
      "药物具有良好的生物利用度和靶向作用于相关通路"
    ],
    "uncertainties": [
      "可能的药物间相互作用和特异性待进一步临床验证"
    ],
    "next_focus_for_pi": [
      "确定是否需要更多临床数据支持次要药物的有效性和适应证"
    ]
  }
}